GlassScriptPhysician profile
Timothy P Baker
NPI 1821079682
$9,006.13
in general payments reported to CMS, 2019-2025
65 companies · $1,006 in 2025
The $1,006 reported for 2025 was more than what 86% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,389 · 2020: $1,035 · 2021: $1,798 · 2022: $1,243 · 2023: $1,131 · 2024: $1,405 · 2025: $1,006.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,542.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,541.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $937.20 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $801.76 | 2019-2025 | Vraylar, Qulipta |
| Astrazeneca Pharmaceuticals LP | $768.41 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Lilly USA, LLC | $738.86 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $616.69 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $477.83 | 2019-2025 | Jardiance |
| Glaxosmithkline, LLC. | $419.06 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Janssen Pharmaceuticals, INC | $328.52 | 2019-2022 | |
| Amgen INC. | $284.33 | 2019-2024 | Repatha, Otezla, Evenity |
| Merck Sharp & Dohme LLC | $282.23 | 2019-2024 | Gardasil 9, Gardasil, Capvaxive |
| Novartis Pharmaceuticals Corporation | $257.33 | 2019-2025 | |
| Abbott Laboratories | $232.72 | 2019-2025 | Freestyle Libre 3, Proclaim |
| Exact Sciences Corporation | $183.44 | 2023-2025 | Cologuard Collection Kit |
| Biohaven Pharmaceutical Holding Company LTD. | $172.14 | 2022 | |
| Amarin Pharma, INC. | $157.78 | 2019-2022 |
Show all 65 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Baker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.